These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 31999031)
1. Evaluation of the anticoagulant effect of low-molecular-weight heparins based on the anti-Xa level during haemodialysis. Tao M; Zheng D; Liang X; Ye M; Liu Y; Li Y; Shen H; He Q Nephrology (Carlton); 2020 Sep; 25(9):723-729. PubMed ID: 31999031 [TBL] [Abstract][Full Text] [Related]
2. Anticoagulation with dalteparin and nadroparin in nocturnal haemodialysis. Verhave G; Weijmer MC; van Jaarsveld BC Neth J Med; 2015 Jul; 73(6):270-5. PubMed ID: 26228191 [TBL] [Abstract][Full Text] [Related]
3. Practical Value of Anti-Xa Activity in the Evaluation of Extracorporeal Circuit Anticoagulation during Haemodialysis: Results of a Cross-Sectional Single-Centre Study. Coene KLM; Dekker MJE; Kerskes MCHM; Hengst M; Schonck MJM; Konings CJAM; Scharnhorst V Nephron; 2017; 137(3):205-211. PubMed ID: 28817831 [TBL] [Abstract][Full Text] [Related]
4. Dose effect relationship of reviparin in chronic hemodialysis: a crossover study versus nadroparin. Reach I; Luong N; Chastang C; Chakroun M; Mirshahi S; Mirshahi MC; Soria J; Desmichels D; Baumelou A Artif Organs; 2001 Jul; 25(7):591-5. PubMed ID: 11493282 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of coagulation and anti-Xa factor when using a heparin-coated AN69ST® dialyser. Sánchez-Canel JJ; Pons-Prades R; Salvetti ML; Seores A; Vázquez M; Pérez-Alba A; Tamarit E; Calvo-Gordo C; Villatoro J Nefrologia; 2012; 32(5):605-12. PubMed ID: 23013946 [TBL] [Abstract][Full Text] [Related]
7. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure]. Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647 [TBL] [Abstract][Full Text] [Related]
8. Effect of low-molecular-weight heparins on anti-Xa peak levels and adverse reactions in Chinese patients with recurrent spontaneous abortion: a single-center, observational study. Bai W; Zhang X; Sun S; Wang Q; Li C; Zhang X; Zhao A BMC Pregnancy Childbirth; 2021 Oct; 21(1):683. PubMed ID: 34620101 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. Guillet B; Simon N; Sampol JJ; Lorec-Penet AM; Portugal H; Berland Y; Dussol B; Brunet P Nephrol Dial Transplant; 2003 Nov; 18(11):2348-53. PubMed ID: 14551364 [TBL] [Abstract][Full Text] [Related]
11. Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis. Stefoni S; Cianciolo G; Donati G; Colì L; La Manna G; Raimondi C; Dalmastri V; Orlandi V; D'Addio F Nephron; 2002; 92(3):589-600. PubMed ID: 12372942 [TBL] [Abstract][Full Text] [Related]
12. A single dose of dalteparin effectively prevents clotting during haemodialysis. Sagedal S; Hartmann A; Sundstrøm K; Bjørnsen S; Fauchald P; Brosstad F Nephrol Dial Transplant; 1999 Aug; 14(8):1943-7. PubMed ID: 10462275 [TBL] [Abstract][Full Text] [Related]
13. A low-molecular-weight heparin (Kabi 2165, 'Fragmin') in repeated use for haemodialysis: prevention of clotting and prolongation of the venous compression time in comparison with commercial unfractionated heparin. Anastassiades E; Ireland H; Flynn A; Lane DA; Curtis JR Nephrol Dial Transplant; 1990; 5(2):135-40. PubMed ID: 2162506 [TBL] [Abstract][Full Text] [Related]
14. Bedside monitoring of anticoagulation in chronic haemodialysis patients treated with tinzaparin. Pauwels R; Devreese K; Van Biesen W; Eloot S; Glorieux G; Vanholder R; Dhondt A Nephrol Dial Transplant; 2014 May; 29(5):1092-6. PubMed ID: 24366900 [TBL] [Abstract][Full Text] [Related]
15. Fondaparinux as an alternative to vitamin K antagonists in haemodialysis patients. Speeckaert MM; Devreese KM; Vanholder RC; Dhondt A Nephrol Dial Transplant; 2013 Dec; 28(12):3090-5. PubMed ID: 24021678 [TBL] [Abstract][Full Text] [Related]
16. Clinical study on low-molecular weight heparin infusion as anticoagulation for nocturnal home haemodialysis. Wong SS; Lau WY; Ng ML; Chan SY; Chan SF; Chan PK; Wan CK; Cheng YL Nephrology (Carlton); 2018 Apr; 23(4):317-322. PubMed ID: 28052451 [TBL] [Abstract][Full Text] [Related]
17. Anticoagulant effects of low-molecular-weight heparins in healthy cats. Alwood AJ; Downend AB; Brooks MB; Slensky KA; Fox JA; Simpson SA; Waddell LS; Baumgardner JE; Otto CM J Vet Intern Med; 2007; 21(3):378-87. PubMed ID: 17552440 [TBL] [Abstract][Full Text] [Related]
18. Factor Xa-activated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis. Frank RD; Brandenburg VM; Lanzmich R; Floege J Nephrol Dial Transplant; 2004 Jun; 19(6):1552-8. PubMed ID: 15034159 [TBL] [Abstract][Full Text] [Related]
19. Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis. Kalicki RM; Aregger F; Alberio L; Lämmle B; Frey FJ; Uehlinger DE Thromb Haemost; 2007 Dec; 98(6):1200-7. PubMed ID: 18064314 [TBL] [Abstract][Full Text] [Related]
20. In vitro anticoagulation monitoring of low-molecular-weight heparin. Wang JQ; Shi XB; Yang JG; Hu DY Chin Med J (Engl); 2009 May; 122(10):1199-202. PubMed ID: 19493471 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]